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Dear Editor, 
Please find as online submission our manuscript entitled Comment   on   “The   Relative  
Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 
1” to be considered for publication in Clinical Infectious Diseases. 
We appreciated the analysis by Kirean and colleagued trying to assess the efficacy of 
telaprevir and boceprevir in the absence of direct comparison trials. We suggest that the 
observed superiority in telaprevir recipients could be justified by the drug longer 
elimination half.life and therefore forgiveness. We therefore apply what we learnt from 
antiretroviral treatment experience and we suggest that adherence should be taken into 
account, measured and enhanced by clinicians and researchers. 
Regarding potential conflicts of interest, no author has specific funding to disclose (a 
transparency declaration is at the end of the document). 
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We hope that this manuscript can be of interest to the readers of CID, and look forward 
to receiving from you. 
Yours truly. 
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Dear Editor,  
in their very comprehensive meta-analysis Dr. Kieran and co-workers compared the 
efficacy of telaprevir and boceprevir as third agents in the treatment of chronic HCV 
hepatitis; they found a significantly greater efficacy rate for telaprevir in the specific 
setting of prior relapsers as compared to standard pegylated interpheron/ribavirin 
(PegIFN/RBV) therapy [1]. Such a meta-analysis is so far the only attempt to compare 
the two new anti-HCV antivirals, which have been released into the market without any 
preference for either agent in treatment recommendations [2].  A number of parameters 
have been proven to influence the outcome of anti-HCV treatment, such as genetic 
variation in IL28B, the type of PegIFN administered, baseline HCV-RNA, RBV 
pharmacokinetic exposure and degree of liver fibrosis. As stated by the Authors, 
dependency of the treatment outcome on the third drug may be thus be rather variable, 
and even of borderline significance when multiple favourable factors coincide in the 
same patient. We think that further to what suggested by the Authors in terms of possible 
reasons accounting for the higher efficacy of telaprevir in prior relapsers, its longer 
elimination half-life (t½, 9-11 hours) as compared to boceprevir (3.4 hours) should also 
be taken into consideration [3,4]. In anti-HIV therapy a longer half-life is the major 
determinant  of  what  we  call  “forgiveness”,  such  as  the  property of maintaining effective 
concentrations in spite of a missed dose of the drug/regimen [5].  In the field of 
antiretroviral therapy, where numerous head-to-head comparisons have been made, a 
tendency to a better virological outcome is almost always recognizable in favour of the 
regimen containing the drug/s with longer half-life [6-8], with the notable exception of 
integrase inhibitors (that being associated with a faster viral clearance may compensate 
for the drug shorter half-life) [9]. Although   patients’   adherence   has   been   far   less  
characterized in the HCV setting than in antiretroviral therapy, we might reasonably 
envisage how patients under triple anti-HCV therapy taking oral drugs three times daily 
are at risk of suboptimal adherence. Supposing an equal degree of non-adherence, 
effective pharmacokinetic exposure of telaprevir persist longer than in case of boceprevir 
intake when a dose is missed, thus allowing a greater chance of maintaining adequate 
antiviral concentration despite of irregular drug intake. This pharmacokinetic property of 
telaprevir has been recently further testified by the successful validation of twice daily 
intake of the drug at equal total daily dose [10]. Since controlled head-to-head 
comparative trials between telaprevir and boceprevir are unlikely to be performed (and 
might soon lose interest with the new anti-HCV drugs being developed) the meta-analytic 
comparison carried out by the Authors might remain the sole to rely upon. Based on these 
considerations we   believe   that   whenever   patient’s   adherence   is   perceived   to   be  
particularly at risk, the choice of telaprevir might provide an advantage in terms of 
pharmacokinetic coverage. 
 
Andrea Calcagno, MD, DTM&H 
Lucio Boglione, MD 
Francesco Giuseppe De Rosa, MD 
Giovanni Di Perri, MD, DTM&H, PhD 
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